Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis receives FDA approval for meningococcal disease vaccine

Novartis receives FDA approval for meningococcal disease vaccine

23rd February 2010

Novartis has had its application for approval of its meningococcal disease vaccine Menveo approved by the Food and Drug Administration (FDA).

The regulator ratified the compound for use as a treatment for adolescents and adults based on positive findings from a phase III trial, during which the drug demonstrated its efficacy in encouraging an immune response to the potentially fatal illness.

This approval represents the culmination of a decade-long development process for Novartis, which described the news as an “important milestone” in the treatment of the disease.

Andrin Oswald, division head of Novartis Vaccines and Diagnostics, stated that the production of treatments for this condition is particularly vital due its potential effect on previously healthy adolescents.

He added that the approval of Menveo is indicative of the company’s commitment to eradicating the illness across the world.

Earlier this month, the company was granted a priority FDA review of its new leukaemia drug Tasigna following promising results from a clinical trial.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.